English
English
Tiếng Việt
ภาษาไทย
繁體中文
한국어
Bahasa Indonesia
Español
Português
zu-ZA
0

Market Analysis

Merck shares fall 9% despite earnings beat, strong demand for top drugs like Keytruda
Amos · 79 Views

B1AA7B36-B649-4b4f-975F-791ED97034A9

 

Merck reported second-quarter revenue and adjusted earnings that topped estimates as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a new cardiovascular drug. 


The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion, however it lowered its adjusted profit guidance to between $7.94 and $8.04 per share.


Shares of Merck fell Tuesday as investors appeared to mull over lighter-than-expected sales of Gardasil.

 

Need Help?
Click Here